60% year-on-year growth in net profit
LiveSpo reported a strong performance in the first half of 2025, with cumulative net profit up by 60% year-on-year, driven by strong sales in pharmacy chains. In May 2025, LiveSpo NAVAX, LiveSpo’s most popular and highly efficacious nasal-spray spore probiotics products was distributed in Pharmacity, the nation’s second largest pharmacy chain, making LiveSpo’s products more accessible to customers.
Established in 2011, LiveSpo is an innovative consumer health company that R&D, manufactures and sells liquid spore-based probiotics supplement for digestive disorders and respiratory enhancement. LiveSpo’s core strength is their ability to provide highly stable spores of Bacillus Clausi, Bacillus Subtills and Bacillus Coagulans, which have been proven to have significant impact on the health of microbiomes in seven body’s entry tracts (mouth, ear, nose, eyes, skin, urinary and anus). LiveSpo’s products are primarily distributed through pharmacies and e-commerce platforms in Vietnam.